Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Apr 11, 2021 11:47am
119 Views
Post# 32974249

RE:RE:RE:RE:RE:RE:RE:The company and only the company

RE:RE:RE:RE:RE:RE:RE:The company and only the companyGood for you Lee! I'm still hiding everything from my wife. I wouldn't sell at $2bil, that's peanuts if either program works out. I don't think Paul would either.  He's young and has a rare chance to make his company into something quite large if he let's it all play out. I also think the developments will happen so quickly if they are positive that the market cap will figure out the revenue potential and be well beyond that level if SORT1 is a reality or NASH is. 

Lee430 wrote: Wasn’t is mentioned here some time ago that someone in Greenspoon’s research group was also collaborating with Pfizer on a project and that Pfizer was most likely aware of the NASH research, was thinking Pfizer should have some fresh capitol from the Covid vaccine profits that would be needing a home and Thera sure would be an attractive place to park it right now…..SP of $200 sounds exciting but honestly I know it would be leaving a lot on the table, however, an offer of $25 would get my vote, that’s only $2B for the whole company so a SP of $200 doesn’t really sound all that crazy.

Wino, I did take your advice on that older post and moved a large percentage of my 401K into Thera, although I did not hide this from my wife let’s just say the info was not offered up until the SP started to rally a bit ;->






<< Previous
Bullboard Posts
Next >>